Immunovant said it will scrap its first-generation FcRn inhibitor after failing to meet efficacy endpoints in pair of Phase 3 eye disease trials. The company confirmed the program’s closure a month after the asset flunked the late-stage studies, according to the announcement. The decision closes the loop on an FcRn strategy aimed at reducing pathogenic immune activity—an approach that has been tested in multiple autoimmune and inflammatory settings—though Immunovant did not outline a broader pivot in the provided prompt. For investors and partners, the termination signals how quickly late-stage failures can reshape development portfolios, especially for first-generation assets with limited differentiation against emerging FcRn programs.